

Supplement Table 2: Immunosuppressive drugs started prior to QuantiFERON® testing among cohort of patients tested due to immunosuppression.

Immunosuppression drug	Pre-order set (n=191)	Post Order Set (n=343)	Total (N=534)
	n (%)	n (%)	n (%)
Steroid (prednisone equivalent)			
<15 mg	1 (1%)	2 (1%)	3 (1%)
15–50 mg	27 (14%)	75 (22%)	102 (19%)
50 mg +	71 (37%)	69 (20%)	140 (26%)
Total	99* (52%)	146** (43%)	245 (46%)
Adalimumab	1 (1%)		1 (<1%)
Chemotherapy	3 (2%)	4 (1%)	7 (1%)
Rituximab		1 (<1%)	1 (<1%)
Mycophenolate mofetil		1 (<1%)	1 (<1%)
Cyclophosphamide		1 (<1%)	1 (<1%)
Total started on one or more ISD	103 (54%)	153 (45%)	256 (48%)

* Of these, 4 patients were also started on an additional ISD prior to QFT collection (adalimumab [1]; rituximab [1]; MMF [2]; chemotherapy [1])

** Of these, 9 patients were also started on an additional ISD prior to QFT collection (rituximab [4]; chemotherapy [2]; cyclophosphamide [2]; elranatamab [1])

ISD: immunosuppressive drug; MMF: mycophenolate mofetil; QFT: QuantiFERON®

